> ## Content Index
> Fetch the complete content index at: https://us.mikirduit.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Sana Biotechnology (SANA) Stock Falls Over 50%: What Investors Should Know Before Buying the Dip
- URL: https://us.mikirduit.com/sana-biotechnology-sana-stock-falls-over-50-what-investors-should-know-before-buying-the-dip/
- Published: 2026-11-13T10:10:32.000Z
- Updated: 2026-11-13T10:10:32.000Z
- Description: Sana Biotechnology (SANA) shares have dropped more than 50% since late August. Its Q3 2026 profit came from a non-cash accounting gain, while cash runway and dilution remain major concerns. Here is what investors should know about the risks and outlook.
- Author: Surya Rianto
- Tags: Earnings Digest, Stocks

**Mikirduit –** Selling pressure increased in the week after Sana Biotechnology (NASDAQ: SANA) published its third-quarter 2026 results. The headline number looked good: a net profit of $20.4 million. For a company with no revenue, that deserves a closer look.

#### The Profit Was an Accounting Gain, Not a Business Improvement

The $63.38 million gain was non-cash. It came from adjusting estimated liabilities tied to past deals:

| Component                                  | Amount             |
| ------------------------------------------ | ------------------ |
| Adjustment to Cobalt acquisition liability | $55.47 million     |
| Adjustment to Cobalt success payment       | $7.63 million      |
| Harvard success payment                    | $0.28 million      |
| **Total non-cash gain**                    | **$63.38 million** |

The largest piece relates to the estimated liability from Sana’s acquisition of Cobalt Biomedicine in 2019\. Such gains arise when a company revises its estimate of what it may owe in the future. They do not mean cash came in or that operations improved.

Excluding the gain, Sana posted a **net loss of about $42.98 million**, or roughly **$0.14 per share** on an adjusted basis. That was in line with analyst expectations of about $0.13 to $0.18 per share. In other words, there was no surprise in the underlying business, and the “profit” was a one-off accounting item.

### What Does Sana Do?

Sana is a clinical-stage biotechnology company. It is developing cell-based therapies but has no approved product to sell, so it generates no revenue and spends cash on research and development. Investors in companies like this are betting on future clinical results.

Sana’s pipeline centers on two main programs.

#### 1\. SC451: A Potential Treatment for Type 1 Diabetes

SC451 aims to let people with type 1 diabetes live without insulin injections. It uses Sana’s hypoimmune (HIP) technology, which modifies cells so the body’s immune system does not attack them. If this works, patients would not need immunosuppressant drugs.

**Evidence so far.** The supporting evidence comes from an earlier study, UP421, which used modified pancreatic cells from human donors:

- One patient was followed for 14 months.
- No safety issues were reported.
- There was no immune rejection of the modified cells.
- The patient had **not yet** become free of external insulin.

**What comes next.** Sana is preparing an Investigational New Drug (IND) application with the U.S. FDA. As of Q3 2026, management still described this as a target, not a confirmed achievement. A Phase 1/2 trial could start as early as the end of 2026\. It would test safety, cell survival, insulin production, blood sugar control, and any reduction in insulin needs.

**Competition.** Vertex Pharmaceuticals is also developing cell therapies for type 1 diabetes and is further along in clinical development. Sana’s advantage is its approach to avoiding immunosuppression.

## Sign up for Mikirduit US

Independent Stock Research, Earnings Analysis, and Valuation for Everyday Investors

Subscribe 

Email sent! Check your inbox to complete your signup. 

No spam. Unsubscribe anytime.

#### 2\. SG293: In-Body CAR-T Therapy for Blood Cancers

SG293 aims to turn a patient’s own immune cells into CAR-T cells inside the body, which could be used against blood cancers. As of November 13, 2026:

- Primate preclinical studies are underway.
- CAR-T formation in animals and selectivity studies have been completed.
- Early preclinical safety data are available.
- A human trial in non-Hodgkin lymphoma (NHL) is targeted for **Q1 2027**, with first human data expected in **H1 2027**.
- If successful, the technology could later be applied to autoimmune diseases.

A related program, **SG227**, would apply the same technology to multiple myeloma but is at a much earlier stage.

#### Pipeline Cuts

In November 2025, Sana discontinued two Phase 1 programs, **SC291** (allogeneic CAR-T for B-cell-mediated autoimmune diseases) and **SC262** (allogeneic CAR-T for cancer). The company said it wanted to focus on SC451 and SG293 because funding was limited.

Under a moderate scenario, a market launch of SC451 or SG293 would likely not come until the **2030s**, and only if clinical trials go well.

[NVDA vs. AMD After the Selloff: Is Nvidia Really “On Sale”?Nvidia is down 29% and AMD is down 21% since early October 2026\. We compare growth, margins, cash flow, valuation, and rate-hike risk so you can judge each stock yourself.![](https://us.mikirduit.com/content/images/icon/Mikirduit-9bf88fba-62f4-46bd-8f2e-4d4d5f991ed0.jpg)Mikirduit USSurya Rianto![](https://us.mikirduit.com/content/images/thumbnail/NVDA-vs-AMD-161aae33-807d-440e-b2bb-3b9220c599ba.jpg)](https://us.mikirduit.com/nvda-vs-amd-after-the-selloff-is-nvidia-really-on-sale/)

### The Main Risk: How Long Will the Cash Last?

For a company with no revenue, cash runway is one of the most important metrics.

#### Runway Calculation

- **Cash as of September 2026:** about $121.7 million
- **Average monthly burn (first 9 months of 2026):** about $12.4 million
- **Implied runway:** roughly 10 months, to about **July 2027**

#### How Sana Could Raise More Money

1. **At-the-market (ATM) offering** through TD Cowen, up to $150 million. This is already in place and is the most likely source.
2. **Private placement** of shares.
3. **Collaborations and licensing**, such as the existing agreement with Mayo Clinic.
4. **Debt or structured financing.** This is difficult for a company without revenue.

#### The Dilution Problem

Using the ATM at the November 12 price of $2.01 per share:

- Raising $150 million would require about **74.6 million new shares**.
- That equals roughly **23.8% dilution** for existing shareholders.
- The runway would extend to roughly **mid-2028**.

The lower the share price falls, the more shares Sana must issue to raise the same amount. This can create a cycle in which dilution pressures the price, which in turn increases the dilution needed. The same dilution pressure has appeared elsewhere in the market. For a comparison, see our analysis of [how a lower share price complicates capital raising for Strategy (MSTR)](https://us.mikirduit.com/strategy-mstr-is-being-dropped-from-msci-indexes-what-happens-nov-30-and-what-it-means-for-investors/).

### Valuation: Why Traditional Metrics Don’t Work

Sana has no revenue, so common measures like price-to-earnings or price-to-sales do not apply. A decline of more than 50% may look like a bargain, but a lower price does not mean the stock is undervalued. The price reflects the market’s assessment of the odds of clinical success, the cost of future dilution, and the time left before the next funding need.

In the near term, the share price is most likely to react to:

- **Clinical and regulatory news**, such as FDA acceptance of the SC451 IND or the start of a Phase 1/2 trial
- **Early human data** from SG293 in 2027
- **Financing announcements**, especially use of the ATM
- **Partnership or acquisition news**

### Possible Scenarios

| Scenario     | What would need to happen                                                           | Likely effect on shares                 |
| ------------ | ----------------------------------------------------------------------------------- | --------------------------------------- |
| **Positive** | Smooth IND filing, encouraging early human data, or acquisition by a larger company | Potentially sharp gains                 |
| **Neutral**  | Slow progress, funding raised through the ATM                                       | Continued volatility, dilution pressure |
| **Negative** | Trial delays or poor data, difficulty raising funds                                 | Further significant declines            |

Two outcomes are the best-case paths for shareholders: development proceeds smoothly, or a larger company acquires Sana.

### Is SANA Suitable for You?

SANA may fit only investors who:

- Understand that clinical-stage biotech is **binary and speculative**
- Can afford to lose the full amount invested
- Can hold for years, since any commercial outcome is likely in the 2030s
- Accept high volatility, as is typical for stocks priced under $10

It is generally **not suitable** for investors who need steady income, capital preservation, or short-term liquidity.

**General risk-management practices** include sizing the position as a small part of a diversified portfolio, avoiding borrowed money, and reading the company’s primary filings yourself.

### Sources and Methodology

This article is based on a report from Mikirduit, published in November 2026, and covers Sana’s Q3 2026 results, pipeline status, share price as of November 12, 2026, and the cash-runway and dilution calculations described above. The runway and dilution figures are estimates built on stated assumptions, such as a constant burn rate and a fixed share price. Actual results will differ.

Before making any decision, verify the figures against primary sources:

- Sana’s Form 10-Q and 8-K filings on the [SEC EDGAR database](https://www.sec.gov/edgar?ref=us.mikirduit.com)
- Sana’s investor relations page and press releases
- ClinicalTrials.gov for trial status
- FDA announcements